Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study

Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study

IntroductionAcromegaly is an uncommon disease with important comorbidity and economic cost. Although the pharmacological cost of second-line treatment for refractory acromegaly has been theoretically analyzed, real-life studies are needed.ObjectivesTo assess the use of pasireotide and pegvisomant in...

Full description

Saved in:
Bibliographic Details
Main Authors: Eva Venegas Moreno, Andrés Jiménez-Sánchez, Pablo Remón-Ruiz, Elena Dios, Jaime Perea Cortés, Celia Hernández-Reina, David A. Cano, Alfonso Soto Moreno
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Endocrinology
Subjects:
acromegaly
pasireotide
pegvisomant
cost analysis
radiotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1573721/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2025.1573721/full

Similar Items